(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-0.15%) $77.99
(0.37%) $2.15
(0.06%) $2 310.10
(0.36%) $26.79
(0.09%) $966.20
(-0.31%) $0.929
(-1.07%) $10.87
(-0.13%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform...
Stats | |
---|---|
本日の出来高 | 1.42M |
平均出来高 | 1.94M |
時価総額 | 1.77B |
EPS | $0 ( 2024-04-04 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 66.67 |
ATR14 | $0.381 (1.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-11 | O'connor Daniel J. | Buy | 750 000 | Common Stock |
2023-10-27 | O'connor Daniel J. | Sell | 50 012 | Common Stock |
2023-10-23 | Cormorant Asset Management, Lp | Buy | 1 307 311 | Common Stock |
2023-09-18 | Cormorant Asset Management, Lp | Buy | 751 233 | Ordinary Shares |
2023-09-15 | Cormorant Asset Management, Lp | Buy | 1 401 505 | Ordinary Shares |
INSIDER POWER |
---|
64.35 |
Last 64 transactions |
Buy: 36 374 710 | Sell: 11 079 608 |
ボリューム 相関
Ambrx Biopharma Inc. 相関
10 最も負の相関 | |
---|---|
LUMN | -0.94 |
KT | -0.934 |
AFI | -0.926 |
QGEN | -0.924 |
GEO | -0.92 |
NSC | -0.917 |
EQC | -0.912 |
UBA | -0.907 |
ATTO | -0.907 |
PDS | -0.906 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ambrx Biopharma Inc. 相関 - 通貨/商品
Ambrx Biopharma Inc. 財務諸表
Annual | 2022 |
収益: | $7.40M |
総利益: | $7.40M (100.00 %) |
EPS: | $-2.02 |
FY | 2022 |
収益: | $7.40M |
総利益: | $7.40M (100.00 %) |
EPS: | $-2.02 |
FY | 2021 |
収益: | $7.46M |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.36 |
FY | 2020 |
収益: | $13.67M |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.439 |
Financial Reports:
No articles found.
Ambrx Biopharma Inc.
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。